GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Nasal Glucagon

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01556594

    Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT01959334

    Evaluate the Immunogenicity of a Novel Glucagon Formulation

    Not yet reported Eli Lilly and Company 75 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Drug-specific Antibodies, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01994746

    Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

    Not yet reported Eli Lilly and Company 77 participants Est. completion 2015-01 8 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01997411

    Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

    Not yet reported, Not yet reported Eli Lilly and Company 48 participants Est. completion 2015-01 7 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02171130

    Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

    Not yet reported Eli Lilly and Company 129 participants Est. completion 2015-08 9 sites Stand-alone
    Other conditions: Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
    View official trial listing →
  • Completed NCT NCT02402933

    Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

    Not yet reported Eli Lilly and Company 26 participants Est. completion 2015-08 3 sites Stand-alone
    Other conditions: Hypoglycemia, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02778100

    A Study of Nasal Glucagon in Participants With a Common Cold

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Common Cold
    View official trial listing →
  • Completed NCT NCT02778113

    A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02806960

    A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

    Not yet reported Eli Lilly and Company 12 participants Est. completion 2014-08 1 site Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02806973

    A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

    Not yet reported Eli Lilly and Company 32 participants Est. completion 2015-04 1 site Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03339453

    A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 70 participants Est. completion 2018-01-13 2 sites Stand-alone
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03421379

    A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

    Not yet reported Eli Lilly and Company 75 participants Est. completion 2018-08-20 4 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03765502

    A Study Comparing User Experience of Different Delivery Devices for Glucagon

    Not yet reported Eli Lilly and Company 99 participants Est. completion 2019-01-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04992312

    A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

    Not yet reported Eli Lilly and Company 7 participants Est. completion 2023-11-05 8 sites Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Nasal Glucagon, Nasal Glucagon (NG)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.